Lyell Immunopharma, Inc. (NASDAQ:LYEL) Director Acquires $94,800.00 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) Director Richard Klausner acquired 158,000 shares of the firm's stock in a transaction on Friday, March 14th. The shares were bought at an average cost of $0.60 per share, with a total value of $94,800.00. Following the completion of the acquisition, the director now owns 843,365 shares in the company, valued at $506,019. This represents a 23.05 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL traded up $0.05 during midday trading on Friday, hitting $0.58. The company's stock had a trading volume of 1,287,155 shares, compared to its average volume of 1,048,095. The firm has a market cap of $170.79 million, a P/E ratio of -0.73 and a beta of -0.41. Lyell Immunopharma, Inc. has a 1-year low of $0.48 and a 1-year high of $3.15. The firm's fifty day moving average price is $0.61 and its 200-day moving average price is $0.88.

Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Wednesday, March 12th. The company reported ($0.72) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.52). The company had revenue of $0.01 million for the quarter. Lyell Immunopharma had a negative net margin of 323,792.09% and a negative return on equity of 34.64%. As a group, research analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current fiscal year.

Remove Ads

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a "neutral" rating and set a $1.00 price target on shares of Lyell Immunopharma in a research report on Thursday, March 13th.

Institutional Investors Weigh In On Lyell Immunopharma

Several large investors have recently added to or reduced their stakes in the stock. Centiva Capital LP acquired a new position in shares of Lyell Immunopharma during the third quarter valued at $31,000. Intech Investment Management LLC acquired a new position in Lyell Immunopharma during the 3rd quarter valued at about $52,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Lyell Immunopharma in the 3rd quarter worth about $52,000. Graham Capital Management L.P. acquired a new stake in shares of Lyell Immunopharma in the fourth quarter valued at approximately $33,000. Finally, Erste Asset Management GmbH bought a new stake in shares of Lyell Immunopharma during the third quarter valued at approximately $82,000. 66.05% of the stock is owned by institutional investors and hedge funds.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.